Announce top-line results from the ongoing dry eye disease field and chamber clinical trials
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Apr 2025
- Due
- 30 Jun 2025
- Delivered
- 5 May 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“In the second quarter of 2025, Aldeyra expects to announce top-line results from the ongoing dry eye disease field trial and the ongoing chamber clinical trial.”
What we found
Evidence strength A What the grades mean
The company announced the results from the dry eye disease field and chamber clinical trials on May 5, 2025, which is within the second quarter of 2025.
-
A Aldeyra Therapeutics, Inc. 10-Q filed 2025-08-07
“On May 5, 2025, we announced the results from the two additional dry eye disease trials. The dry eye chamber trial achieved the primary endpoint (P=0.002) of reducing patient-reported ocular discomfort in a dry eye chamber.” ✓ confirmed on the page
Market reaction: the shares moved +0.1% against the S&P 500 over the three sessions around the disclosure (6 Aug 2025 to 11 Aug 2025). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Announce
- Deliverable
- top-line results from dry eye disease trials
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ALDX-003559 · Corrections policy